OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Location serves as the US flagship for company’s global pharma development network.
Seqens Group, a contract development and manufacturing organization (CDMO), has officially opened its new R&D center in Devens, MA. The 15,000 square-foot lab, boosted by a $5 million investment, serves as the company’s North American flagship for its global R&D network, which consists of 10 centers across Europe and the US and more than 300 scientists.
The facility replaces an older, smaller R&D center in Devens. According to Seqens, all current employees have moved to the new location, with the company planning to double the number of scientists there by 2026. The focus of the center, Seqens adds, is to accelerate development of active pharmaceutical ingredients (APIs) and excipients, including lipids used for the manufacture of RNA vaccines for COVID-19.
The company works with such technologies as flow chemistry and biocatalysis. Unrelated to the opening, it notes that to combat a shortage of paracetamol (acetaminophen) in the US, Seqens is building a plant in France to produce over half of Europe’s paracetamol needs.
Read more about the new facility here.